Some studies suggested a role for B cells in the pathogenesis of NASH and BAFF was shown to be elevated [110,136,137], thus targeting BAFF with the monoclonal antibody belimumab might be feasible. Here, TNFSF13B is linked to metabolic dysfunction-associated steatohepatitis.